Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

GlobeNewswire Inc. | Nov 9, 2026 4:05 PM EST

Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD)